Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Macarulla Mercade, T. [1 ,2 ]
Wang-Gillam, A. [3 ]
Chen, L. [4 ]
Blanc, J. [5 ]
Lee, K. [6 ]
Bodoky, G. [7 ]
Dean, A. [8 ]
Siveke, J. [9 ,10 ,11 ]
Mirakhur, B. [12 ]
Chen, J. [13 ]
de Jong, F. [14 ]
机构：
[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Washington Univ, Div Oncol, St Louis, MO USA
[4] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan
[5] Hop Haut Leveque, Bordeaux, France
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Szent Laszlo Hosp, Dept Oncol, Budapest, Hungary
[8] St John God Hosp Subiaco, Subiaco, WA, Australia
[9] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[10] German Canc Consortium DKTK, Essen, Germany
[11] German Canc Res Ctr, Essen, Germany
[12] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[13] Shire Plc, Cambridge, MA USA
[14] Shire Int GmbH, Glattpk Opfikon, Switzerland
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 150
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Subgroup Analysis by Measurable Metastatic Lesion Number and Selected Lesion Locations at Baseline in NAPOLI-1: A Phase III Study of Liposomal Irinotecan +/- 5-Fluorouracil/Leucovorin in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Previously Treated With Gemcitabine-Based Therapy
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 10 - 12
  • [32] Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla, Teresa Mercade
    Siveke, Jens T.
    Dean, Andrew Peter
    Hubner, Richard
    Blanc, Jean-Frederic
    Cunningham, David
    Chen, Li-Tzong
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [34] Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Siveke, Jens T.
    Hubner, Richard
    Macarulla, Teresa Mercade
    Wang-Gillam, Andrea
    Dean, Andrew Peter
    Blanc, Jean-Frederic
    Cunningham, David
    Mirakhur, Beloo
    Belanger, Bruce
    de Jong, Floris A.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [35] An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma
    Suzuki, Rei
    Takagi, Tadayuki
    Hikichi, Takuto
    Sugimoto, Mitsuru
    Konno, Naoki
    Asama, Hiroyuki
    Watanabe, Ko
    Nakamura, Jun
    Marubashi, Shigeru
    Ohira, Hiromasa
    ONCOLOGY LETTERS, 2019, 17 (01) : 587 - 593
  • [36] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen Li-Tzong
    Andrea, Wang-Gillam
    Shan Yan-Shen
    Teresa, Macarulla
    Jean-Frederic, Blanc
    Richard, Hubner
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Jens, Siveke
    Marc, Pipas J.
    Bruce, Belanger
    Floris, de Jong
    Khalid, Mamlouk
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
    Sanoyan, Dilara Akhoundova
    Reiner, Caecilia S.
    Papageorgiou, Panagiota
    Siebenhuener, Alexander R.
    CASE REPORTS IN ONCOLOGY, 2020, 13 (01): : 79 - 84
  • [38] Real-world treatment patterns and effectiveness of liposomal irinotecan in a NAPOLI1-based regimen among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): A multi-academic center chart review
    Yu, K. H.
    Hendifar, A.
    Alese, O.
    Draper, A.
    Abdelrahim, M.
    Burns, E.
    Khan, G.
    Cockrum, P.
    Bhak, R.
    Nguyen, C.
    DerSarkissian, M.
    Duh, M. S.
    Bahary, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S950 - S951
  • [39] NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Wainberg, Zev A.
    Melisi, Davide
    Macarulla, Teresa
    Pazo-Cid, Roberto
    Chandana, Sreenivasa R.
    De La Fouchardiere, Christelle
    Dean, Andrew Peter
    Kiss, Igor
    Lee, Woojin
    Goetze, Thorsten Oliver
    Van Cutsem, Eric
    Paulson, Andrew Scott
    Bekaii-Saab, Tanios S.
    Pant, Shubham
    Hubner, Richard
    Xiao, Zhimin
    Chen, Huanyu
    Benzaghou, Fawzi
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA661 - LBA661
  • [40] OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Geboes, Karen Paula
    Cassier, Philippe Alexandre
    Lambert, Aurelien
    Mitry, Emmanuel
    Prenen, Hans
    Pilla, Lorenzo
    Blanc, Jean-Frederic
    Gallego Jimenez, Inmaculada
    Cid, Roberto A. Pazo
    Rodriguez Garrote, Mercedes
    Feliu, Jaime
    Nordbladh, Karin
    Smith, Karin Enell
    Gomez Jimenez, David
    Ellmark, Peter
    Pico de Coa, Yago
    Ambarkhane, Sumeet Vijay
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345